State Prescriber Information

Information for Colorado Prescribers

In accordance with Colorado law, Blueprint Medicines is disclosing wholesale acquisition cost (“WAC”) pricing information for its marketed products. WAC represents the manufacturer’s published catalog or list price for a drug product to wholesalers or distributors, as reported to third‑party drug price compendia by the manufacturer. WAC does not represent actual transaction prices and does not include discounts, rebates, or other reductions in price. In many cases, the price paid by patients will be different from the reported WAC. How much a patient will pay will depend on the patient’s insurance coverage. To determine the exact cost of a prescription, patients should contact their health insurance provider or specialty pharmacy.

Information for Connecticut prescribers

In accordance with Connecticut law, Blueprint Medicines is disclosing wholesale acquisition cost (“WAC”) pricing information for its marketed products. WAC represents the manufacturer’s published catalog or list price for a drug product to wholesalers or distributors, as reported to third‑party drug price compendia by the manufacturer. WAC does not represent actual transaction prices and does not include discounts, rebates, or other reductions in price. In many cases, the price paid by patients will be different from the reported WAC. How much a patient will pay will depend on the patient’s insurance coverage. To determine the exact cost of a prescription, patients should contact their health insurance provider or specialty pharmacy.

Information for Vermont Prescribers

In accordance with Vermont law, Blueprint Medicines is disclosing average wholesale price (“AWP”) information for its marketed products and other drugs in the same therapeutic class. AWP does not represent actual transaction prices and does not include discounts, rebates, or other reductions in price. In many cases, the price paid by patients will be different from the reported AWP. How much a patient will pay will depend on the patient’s insurance coverage. To determine the exact cost of a prescription, patients should contact their health insurance provider or specialty pharmacy.

GAVRETO® (pralsetinib) is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines’ collaboration with Roche. View GAVRETO information for Colorado, Connecticut and Vermont Prescribers via Genentech.